BioXcel Therapeutics - Chapter 11 DIP Terms

BioXcel Therapeutics obtained final approval of its $77.25 million multi-draw priming DIP facility from lenders that hold 100% of its prepetition secured debt. The facility carries $19 million of new money, a $9.5 million initial draw funded at closing and an additional draw of up to $9.5 million unlocked by the final order, plus a cashless, dollar-for-dollar roll-up of up to $58.25 million of prepetition debt: $1.25 million of bridge obligations and $28.5 million at closing, and a further $28.5 million on funding of the additional draw. The lenders agreed to waive the administrative priority of the roll-up portion of their superpriority claims, up to the roll-up principal, to the extent plan distributable value falls short of administrative and priority claims.

DIP Terms

Borrower / Guarantors

Agent / Lenders

DIP Commitments

Interest Rate

Fees

Maturity / Termination

Events of Default and Remedies

Carve Out

Use of Proceeds

Cash Collateral

Securities and Priorities

Adequate Protection

Prepetition Secured Parties

Waivers

Release

Credit Bid

Avoidance Actions

Debtors' Stipulations

Challenge Period and Budget

Permitted Variance

Key Dates